Aptevo Therapeutics amends shareholder rights agreement, extends expiration to 2027

Aptevo Therapeutics Inc. disclosed in an 8-K filing that on October 23, 2026, the company entered into Amendment No. 6 to its Rights Agreement, originally dated November 8, 2020, between the company and Broadridge Corporate Issuer Solutions, LLC, as rights agent.¹

The underlying agreement concerns contingent rights to purchase one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001, of the company.¹

The amendment makes two changes. First, it extends the definition of "Final Expiration Date" and certain related language in the Rights Agreement to October 23, 2027.¹ Second, it changes the definition of "Purchase Price" and certain related language in the Rights Agreement to $14.56 per one one-thousandth of a Preferred Share.¹

The filing notes that the description of the amendment in the 8-K is not complete and is qualified in its entirety by reference to the full text of the amendment, which is attached as Exhibit 4.1 to the filing.¹

Aptevo also reported the matter under Item 3.03, Material Modification to Rights of Security Holders, incorporating the same information disclosed under Item 1.01 by reference.¹

The amendment, dated October 23, 2026, between the company and Broadridge Corporate Issuer Solutions, LLC as rights agent, was filed as Exhibit 4.1 to the Form 8-K.¹ The report was signed on behalf of Aptevo by Daphne Taylor, Senior Vice President and Chief Financial Officer, on October 23, 2026.¹